Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III ...
Leadership
Todd C. Brady M.D., Ph.D.
CEO, President & Director
Michael Alfieri
Head of Finance and Principal Financial & Accounting Officer
David Burke
Head of Investor Relations
Laura Nichols
Operations Manager
Adam Lazorchak
Director of Translational Sciences & Non-Clinical Development
